You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 1616 results
 
  • Record 1 TO 1000
  • Record 1001 TO 1616

  1. RADIOSURGICAL TREATMENT IN THE THORAX AND ABDOMEN

    SBC: Accuray Incorporated            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services

  2. An Epithermal Neutron Source for Cancer Therapy

    SBC: ADELPHI TECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a commercial neutron source for the treatment of brain and liver cancer based on boron neutron capture therapy (BNCT). Boron-containing compounds are injected into a patient's bloodstream and accumulate in a malignant tumor. When irradiated with neutrons, the boron atoms preferentially capture neutrons and decay, releasing short-range radi ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health

  3. N/A

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  4. N/A

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  5. N/A

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  6. N/A

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health

  7. Novel A2A Adenosine Agonists in Vascular Protection

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health

  8. A2A ADENOSINE AGONIST ADJUNCT FOR SYSTEMIC ANTHRAX

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This project develops A2A adenosine receptor (A2AAR) agonists as adjuncts to antibiotics for the treatment of anthrax septicemia. It responds to the urgent need for better treatment of highly lethal infections by this bioterrorism/biowarfare agent. Phase I has two aims, pharmaceutical development and documentation of efficacy in clinically relevant settings. Th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health

  9. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health

  10. A2A ADENOSINE AGONISTS LIMIT DAMAGE FROM INFECTION

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    epsis syndrome is the 11th leading cause of death in the United States ( about 900,000 new cases per year) with a mortality of about 35 percent. The need for adjunctive therapies is urgent. In Phase I of this SBIR award we documented the anti-inflammatory effects of adenosine A2A receptor (A2AAR) agonists on isolated immune cells and have observed ramatically improved survival in mouse models of I ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government